We show that MitoTEMPO, a mitochondrial ROS scavenger, reversed the cytotoxic effects of IFNγ/phenformin combination treatment in three independent breast cancer models (MT4788, MDA-MB-231, and BT474) (Fig. 4c–e). Here, IFNG is linked to breast carcinoma.